Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol vs iron sucrose for iron deficiency anemia in pediatric chronic kidney disease
2017-004026-15Phase 3Active
- Sponsor
- AMAG Pharmaceuticals, Inc.
- Start
- Mar 2018
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferumoxytol in iron deficiency anemia (IDA) and chronic kidney disease (CKD) (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoints: Safety compared to iron sucrose and Efficacy of ferumoxytol. Started Mar 2018; status: active.
02
Drugs
ferumoxytol
03
Conditions
iron deficiency anemia (IDA)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2017-004026-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004026-15.